Organigram And This Canadian Cannabis Brand Expand In Europe And Beyond
Organigram And This Canadian Cannabis Brand Expand In Europe And Beyond
Germany's recent legislative push in the cannabis sector marks a significant turning point not only for the country but also for the European cannabis landscape.
德国最近在大麻领域的立法举措不仅标志着该国的重大转折点，也是欧洲大麻格局的重大转折点。
Europe has become more open-minded about medical and recreational marijuana over the recent years, which is why growing number of the North American cannabis operators venturing into the new market comes as no surprise.
近年来，欧洲对医用和休闲大麻变得更加开放，这就是为什么越来越多的北美大麻经营者冒险进入新市场不足为奇的原因。
The burgeoning European market will be one of many hot topics at Benzinga's fall cannabis event. Hear directly for top executives, investors, policymakers and advocates at the 19th Benzinga Cannabis Capital Conference, coming to Chicago this Oct. 8-9. Get your tickets now before prices surge by following this link.
蓬勃发展的欧洲市场将成为Benzinga秋季大麻活动的众多热门话题之一。在将于10月8日至9日在芝加哥举行的第19届Benzinga大麻资本会议上，直接听取高层管理人员、投资者、政策制定者和倡导者的意见。点击此链接，立即在价格飙升之前获取门票。
Organigram Expands Cannabis Supply Network In UK
Organigram扩大了英国的大麻供应网络
On Tuesday, Toronto-based cannabis giant Organigram Holdings Inc. (NASDAQ:OGI) (TSX:OGI) announced its second international medical cannabis customer in the UK, Avida Medical, a full-service medical cannabis and specials medicines manufacturing business.
周二，总部位于多伦多的大麻巨头Organigram Holdings Inc.（纳斯达克股票代码：OGI）（多伦多证券交易所股票代码：OGI）宣布了其在英国的第二个国际医用大麻客户——Avida Medical，这是一家提供全方位服务的医用大麻和特殊药品制造公司。
Subject to the terms of the deal, the company expects to supply 1,700 kilograms of high-quality, indoor-grown dried cannabis flower to Avida Medical in the UK over three years.
根据交易条款，该公司预计将在三年内向英国Avida Medical供应1,700公斤高质量的室内种植干大麻花。
Tim Emberg, chief commercial officer of Organigram praised the move and the "immense potential of the UK market."
Organigram首席商务官蒂姆·恩伯格对这一举动以及 “英国市场的巨大潜力” 表示赞赏。
"We are pleased to partner with Avida Medical in the UK, marking yet another exciting milestone for Organigram's expansion into the global market," Emberg said. "Our decision to further expand into this market stems from our commitment to ensuring patients have access to reliable, high-quality medical cannabis offerings."
恩伯格说：“我们很高兴与英国Avida Medical合作，这标志着Organigram向全球市场扩张的又一个激动人心的里程碑。”“我们决定进一步向这个市场扩张，源于我们对确保患者获得可靠、高质量的医用大麻产品的承诺。”
See also: Weed Giants Tilray And Curaleaf Ramp Up Presence In Europe, Here's Why
另见：大麻巨头 Tilray 和 Curaleaf 扩大在欧洲的影响力，原因如下
Ghost Drops, The Canadian Cannabis Brand Expands Globally
Ghost Drops，加拿大大麻品牌向全球扩张
Meanwhile, Canadian cannabis brand Ghost Drops announced an exclusive partnership with SOMAÍ Group, an international cannabinoid biopharma company with distribution channels.
同时，加拿大大麻品牌Ghost Drops宣布与拥有分销渠道的国际大麻素生物制药公司索迈集团建立独家合作伙伴关系。
Under the supply and distribution deal, Ghost Drops-branded products will initially be rolled out across Europe, the United Kingdom and Australia.
根据供应和分销协议，Ghost Drops品牌的产品最初将在欧洲、英国和澳大利亚推出。
The agreement positions the company to capture market share in cannabis markets across Europe and internationally.
该协议使该公司能够占领欧洲和国际大麻市场的市场份额。
"Together, SOMAÍ Group and Ghost Drops will introduce European, U.K., and Australian markets to top-tier Canadian cannabis products, bringing quality relief to patients internationally," said Tom Flow, managing director of SOMAÍ Group's subsidiary RPK Biopharma.
索迈集团子公司RPK Biopharma董事总经理汤姆·弗洛表示：“索迈集团和Ghost Drops将共同向欧洲、英国和澳大利亚市场介绍加拿大顶级大麻产品，为国际患者带来质量缓解。”
Now read: Cannabis On The Rise In Europe: Why Germany's Legalization Is A Game Changer For The Ecosystem
立即阅读：大麻在欧洲崛起：为什么德国的合法化改变了生态系统的游戏规则
OGI Price Action
OGI 价格走势
Organigram's shares traded 2.75% higher at $1.87 per share during the pre-market session on Tuesday morning.
在周二上午的盘前交易中，Organigram的股价上涨了2.75％，至每股1.87美元。